Who is really a candidate for active surveillance (AS) as opposed to early treatment for prostate cancer that is supposedly localized is not yet well-defined. Indeed, it may not even be possible to come up with any “absolute” guidelines for eligibility for AS based on the diagnostic and prognostic tools we have at this time.
Filed under: Management | Tagged: active surveillance, expectant managemt, outcomes | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site
